ArticleThoracic cancer2025

Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.

Wensi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.